Oncotarget

In The News - Press Releases


Oncotarget: PIP3-binding proteins promote limit survival in C. elegans


FOR IMMEDIATE RELEASE
2020-12-07

Here is a link to a video interview with Dr. Robert J. Shmookler Reis and Dr. Srinivas Ayyadevara about this research on the Oncotarget Youtube Channel

Oncotarget published "PIP3-binding proteins promote age-dependent protein aggregation and limit survival in C. elegans" which reported that Class-I phosphatidylinositol 3-kinase converts phosphatidylinositol 4,5-bisphosphate to phosphatidylinositol 3,4,5-triphosphate.

Proteins with domains that specifically bind that head-group are thus tethered to the inner plasma-membrane surface where they have an enhanced likelihood of interaction with other PIP3-bound proteins, in particular other components of their signaling pathways.

Null alleles of the C. elegans age-1 gene, encoding the catalytic subunit of PI3KI, lack any detectable class-I PI3K activity and so cannot form PIP3. These mutant worms survive almost 10-fold longer than the longest-lived normal control, and are highly resistant to a variety of stresses including oxidative and electrophilic challenges.

The authors used ligand-affinity capture to identify membrane-bound proteins downstream of PI3KI that preferentially bind PIP3. Computer modeling supports a subset of candidate proteins predicted to directly bind PIP3 in preference to PIP2, and functional testing by RNAi knockdown confirmed candidates that partially mediate the stress-survival, aggregation-reducing and longevity benefits of PI3KI disruption.

In this Oncotarget study, PIP3-specific candidate sets are highly enriched for proteins previously reported to affect translation, stress responses, lifespan, proteostasis, and lipid transport.

In this Oncotarget study, PIP3-specific candidate sets are highly enriched for proteins previously reported to affect translation, stress responses, lifespan, proteostasis, and lipid transport.

Dr. Robert J. Shmookler Reis and Dr. Srinivas Ayyadevara both from The Central Arkansas Veterans Healthcare Service as well as The University of Arkansas at Little Rock said, "Class-I phosphatidylinositol 3-kinase (PI3KI) is the enzyme responsible for converting phosphatidylinositol 4,5-bisphosphate (PIP2) to phosphatidylinositol 3,4,5-triphosphate (PIP3)"

However, very few proteins in these families have been shown to preferentially bind PIP3, and protein homology has proven insufficient to identify PIP3-specific binding.

Figure 8: Survivals of C. elegans exposed from the late-larval (L4) stage, to RNAi targeting genes that encode two PIP3-binding proteins. Data were combined from 4 experiments with N2 wild-type worms (A) or from 2 experiments with daf-16(m26) mutant worms (B) exposed to empty feeding vector (FV) or RNAi targeting cand-1 or rad-50. Total numbers of uncensored/censored deaths included were (A) control, 148/7; cand-1 RNAi, 82/2; and rad-50 RNAi, 114/6; and (B) control, 88/2, cand-1 RNAi, 90/0; and rad-50 RNAi, 87/3. *Gehan-Wilcoxon log-rank P < 3E-4; **Gehan-Wilcoxon log-rank P < 1E-4

We used PIP3- and PIP2-affinity enrichment to compare proteins from isogenic strains that differ genetically in their ability to make PIP3, coupled to proteomic identification of the binding proteins.

Molecular modeling of proteins that show preferential binding to PIP3 over PIP2 allows us to extend structural prediction beyond PH-domain proteins, with the potential for confirmation by functional testing.

Proteins with reported specificity for PIP3 include the serine/threonine kinases AKT and PDK-1; Phospholipase C isoforms; atypical protein kinase C, aPKC; cytohesins; general receptor for phosphoinositides 1, GRP1; kindlin3; IL-2 inducible T-cell kinase, ITK; Skap-hom; and Arf GTPase-activating protein 1.

Protein domains reported to confer PIP3-specific binding in some proteins include pleckstrin homology domains, Phox-homology and FYVE domains, P2X domains, and the SYLF domain

The Shmookler Reis/Ayyadevara Research team concluded in their Oncotarget Priority Research Paper that In view of the importance of PI3KI as a driver of cell proliferation, inhibitors have been actively sought as potential chemotherapeutic agents for cancer.

In pursuit of novel anti-cancer drugs, and equally in seeking drugs to prevent or ameliorate Alzheimer's and other age-dependent diseases, potential therapeutic benefits of PI3KI inhibitors have been overshadowed by the virtual certainty that they would also be detrimental to stem cell niches.

This concern has motivated our search for PIP3-binding proteins as alternative targets downstream of PI3KI.

Among these, AKT is believed to drive most of the proliferative effects of PI3K, whereas RAD50, CAND1, FAT2 and TCT1 constitute novel targets that may preserve survival benefits of PI3KI disruption, uncoupled from blockage of cell proliferation.

Sign up for free Altmetric alerts about this article

DOI - https://doi.org/10.18632/oncotarget.10549

Full text - https://www.oncotarget.com/article/10549/text/

Correspondence to - Robert J. Shmookler Reis - rjsr@uams.edu and Srinivas Ayyadevara - AyyadevaraSrinivas@uams.edu

Keywords - phosphatidylinositol 3-kinase, phosphatidylinositol 3,4,5-triphosphate (PIP3), longevity, oxidative stress resistance, protein aggregation

About Oncotarget

Oncotarget is a biweekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.

To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with:

SoundCloud - https://soundcloud.com/oncotarget
Facebook - https://www.facebook.com/Oncotarget/
Twitter - https://twitter.com/oncotarget
LinkedIn - https://www.linkedin.com/company/oncotarget
Pinterest - https://www.pinterest.com/oncotarget/
Reddit - https://www.reddit.com/user/Oncotarget/

Oncotarget is published by Impact Journals, LLC please visit http://www.ImpactJournals.com or connect with @ImpactJrnls

Media Contact
MEDIA@IMPACTJOURNALS.COM
18009220957x105



Copyright © 2021 Impact Journals, LLC
Impact Journals is a registered trademark of Impact Journals, LLC